Synthetic progestins used in HRT have different glucocorticoid agonist properties.
about
Identification of a regulatory loop for the synthesis of neurosteroids: a steroidogenic acute regulatory protein-dependent mechanism involving hypothalamic-pituitary-gonadal axis receptorsMolecular modulation of estrogen-induced apoptosis by synthetic progestins in hormone replacement therapy: an insight into the women's health initiative studyThe injectable-only contraceptive medroxyprogesterone acetate, unlike norethisterone acetate and progesterone, regulates inflammatory genes in endocervical cells via the glucocorticoid receptor.Sex steroid hormones, hormonal contraception, and the immunobiology of human immunodeficiency virus-1 infection.Sex differences in cognitive impairment and Alzheimer's disease.Medroxyprogesterone acetate alters Mycobacterium bovis BCG-induced cytokine production in peripheral blood mononuclear cells of contraceptive users.Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effectsMedroxyprogesterone acetate differentially regulates interleukin (IL)-12 and IL-10 in a human ectocervical epithelial cell line in a glucocorticoid receptor (GR)-dependent mannerSynthetic gestagens exert differential effects on arterial thrombosis and aortic gene expression in ovariectomized apolipoprotein E-deficient miceThe progestin-only contraceptive medroxyprogesterone acetate, but not norethisterone acetate, enhances HIV-1 Vpr-mediated apoptosis in human CD4+ T cells through the glucocorticoid receptor.Degradation of progestagens by oxidation with potassium permanganate in wastewater effluentsImpact of glucocorticoid receptor density on ligand-independent dimerization, cooperative ligand-binding and basal priming of transactivation: a cell culture model.What goes on behind closed doors: physiological versus pharmacological steroid hormone actions.Mechanisms responsible for progesterone's protection against lordosis-inhibiting effects of restraint I. Role of progesterone receptorsMolecular mechanisms linking high dose medroxyprogesterone with HIV-1 risk.Medroxyprogesterone acetate increases HIV-1 infection of unstimulated peripheral blood mononuclear cells in vitro.The new biology of estrogen-induced apoptosis applied to treat and prevent breast cancer.Fourth-Generation Progestins Inhibit 3β-Hydroxysteroid Dehydrogenase Type 2 and Modulate the Biosynthesis of Endogenous Steroids.The hypersensitive glucocorticoid response specifically regulates period 1 and expression of circadian genesProgesterone and neuroprotectionThe molecular, cellular and clinical consequences of targeting the estrogen receptor following estrogen deprivation therapy.Hormonal contraception and HIV-1 infection: medroxyprogesterone acetate suppresses innate and adaptive immune mechanismsThe intracellular progesterone receptor regulates CD4+ T cells and T cell-dependent antibody responsesThe contraceptive depot medroxyprogesterone acetate impairs mycobacterial control and inhibits cytokine secretion in mice infected with Mycobacterium tuberculosis.Progesterone-induced neuroprotection: factors that may predict therapeutic efficacy.Effect of hormonal contraception on the function of plasmacytoid dendritic cells and distribution of immune cell populations in the female reproductive tractEffect of progestins on immunity: medroxyprogesterone but not norethisterone or levonorgestrel suppresses the function of T cells and pDCsModulation of transcription parameters in glucocorticoid receptor-mediated repression.Characterization of a novel telomerase-immortalized human endometrial stromal cell line, St-T1bDifferential glucocorticoid receptor-mediated effects on immunomodulatory gene expression by progestin contraceptives: implications for HIV-1 pathogenesis.Progesterone induces progesterone receptor gene (PGR) expression via rapid activation of protein kinase pathways required for cooperative estrogen receptor alpha (ER) and progesterone receptor (PR) genomic action at ER/PR target genes.Menopausal estrogen therapy and non-Hodgkin's lymphoma: A post-hoc analysis of women's health initiative randomized clinical trial.Effect of prolonged in vivo administration of progesterone in pregnancy on myometrial gene expression, peripheral blood leukocyte activation, and circulating steroid hormone levels.Parent and conjugated estrogens and progestagens in surface water of the Santa Ana River: Determination, occurrence, and risk assessment.Characterization of Oryzias latipes glucocorticoid receptors and their unique response to progestins.Comparing the androgenic and estrogenic properties of progestins used in contraception and hormone therapy.Effects of medroxyprogesterone acetate on cerebral oedema and spatial learning performance after traumatic brain injury in rats.Hormonal Contraceptives Differentially Suppress TFV and TAF Inhibition of HIV Infection and TFV-DP in Blood and Genital Tract CD4+ T cells.Norethindrone substituted for megestrol in the treatment of metastatic endometrial carcinoma: Three cases.Hormonal Contraception and HIV-1 Acquisition: Biological Mechanisms.
P2860
Q24645044-399E1E58-37A1-4D0F-8666-2E281957A260Q28249558-36AB718C-37FF-42BA-9EDF-3E4EC7261C03Q33631772-A02BFD64-D0EB-4B50-B6E2-A5F4B787E93FQ33779655-AE99CD26-FE73-478F-AC59-35ABB4CEC7D4Q33864547-8E7FAC82-3F1D-4FFA-B5F7-1D655BCBA0D1Q34023815-83921776-D13C-4494-9871-4E6DD1D51CA3Q34317537-1FC5CF8C-922D-44A2-814D-0022E31CD8D5Q34467518-F033CED1-B0E4-4D1C-AC88-5D62D6E80381Q34619444-B0D027B8-7581-404D-BC4C-523C54B25D6BQ34712821-DBBB9C47-5E1F-4EEB-8C7A-868F1A47E4C3Q34723874-FF51E02D-487A-4CB8-89D2-844C3FFBB3ACQ34746416-50E21FE3-FAE1-468A-9BDF-495D5503615BQ34795516-86935EAB-3D26-4436-A9EE-20476E1D1EBEQ35078653-4963C26E-2565-4427-B998-7B8207CD42B4Q35208283-793B2643-8FCE-4909-96CA-369471AAB5E0Q35676330-09DEA2C9-757E-46CC-97F0-05B37B7C2D5BQ35827822-B0C83C61-B5F0-46F5-B230-E6D37BF28853Q36153866-8AADAEA6-D6CE-4B7D-A374-AA0FDB45C704Q36197083-1F5600A6-3C92-446F-B699-A2D37E710E73Q36306281-A0772BBE-9A1B-4DED-9794-E3EF9C700011Q36598699-3945E731-1992-451F-9F9B-43ECCF35E699Q36628484-ACF633EA-3B16-4B98-BD5C-C620E06E7AC3Q36628601-425EA152-B84C-4993-ABCC-2F1D5E8AA16FQ36804689-C6210C9C-F7E1-4585-A771-C5F5681CE69FQ36902093-054A95A2-92B4-438B-9BAA-141663C1A206Q36921893-9F559204-7716-4AD5-89B5-F38572AC3EDFQ36921898-7D4BC8BB-ECEA-4CD7-A73E-4C16F8163433Q37143831-DD4A17CC-8823-4BDC-B9A5-2180A0081801Q37285816-437C30F6-F728-4EB7-A31B-42BA00AAB8DFQ38189088-890B0A2A-59B7-4134-AFF0-B44FD0E8ACAAQ38745523-2F98641C-D430-401F-8EA8-136BA456EF94Q40544175-B348ED92-27D8-4AB0-9B71-1BAD7568AD84Q42740704-6AAC801F-8053-42B3-926A-A51D4C479421Q45938092-8639BA81-D22F-4829-B805-0C5F09DBE69EQ46110181-BA7A1138-D30B-4B71-8280-8EE7FF84C79FQ46632887-704ACBCF-6024-4410-86E9-4CAFE80321ECQ46778835-3AC00248-60C4-4F39-98E9-B6E9AF2D0D8AQ47151161-D87FDDDC-3BCD-42A1-A17E-25DF0BD3955FQ47163058-C9423065-A309-47FE-B32D-E5A5C132EAA2Q47198102-2CD2D208-B640-4DF9-A878-59A2B08D5282
P2860
Synthetic progestins used in HRT have different glucocorticoid agonist properties.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Synthetic progestins used in HRT have different glucocorticoid agonist properties.
@en
type
label
Synthetic progestins used in HRT have different glucocorticoid agonist properties.
@en
prefLabel
Synthetic progestins used in HRT have different glucocorticoid agonist properties.
@en
P50
P1476
Synthetic progestins used in HRT have different glucocorticoid agonist properties.
@en
P2093
Dominique Koubovec
Elisabeth Stubsrud
P356
10.1016/J.MCE.2005.07.001
P577
2005-10-01T00:00:00Z